How did IBRX's Q1 2025 EPS forecast compare to past trends?

ImmunityBio's (IBRX) Q1 2025 EPS forecast of -$0.62 is generally in line with the company's historical EPS trends over the past decade, with a few notable exceptions:

1. **Consistency with Historical Trends**: The projected EPS of -$0.62 for Q1 2025 falls within the range of the company's most recent past EPS values, such as -$0.59 for Q4 2020 and -$0.62 for Q4 2024. This suggests that the company's financial performance in the upcoming quarter may not deviate significantly from its recent historical norms.
2. **Improvement over Previous Quarters**: The EPS of -$0.62 for Q1 2025 represents an improvement compared to the EPS of -$1.22 for Q4 2018 and the EPS of -$1.47 for Q4 2016. This indicates a general upward trend in the company's financial performance over the past decade, with the Q1 2025 forecast representing a positive step forward.
3. **Challenging Comparisons with Earlier Years**: However, it's important to note that the EPS of -$0.62 for Q1 2025 is significantly higher than the EPS of -$3.31 for Q4 2015. This suggests that while the company has made progress in terms of profitability since then, the absolute value of the EPS remains substantial, potentially indicating ongoing challenges for the company.

|code|Ticker|Name|Date|Diluted EPS (FY) YoY|Diluted EPS (FY)|market_code|
|---|---|---|---|---|---|---|
|IBRX|IBRX.O|ImmunityBio|2015|-341.33333333333337|-3.31|185|
|IBRX|IBRX.O|ImmunityBio|2016|55.58912386706949|-1.47|185|
|IBRX|IBRX.O|ImmunityBio|2017|18.367346938775512|-1.2|185|
|IBRX|IBRX.O|ImmunityBio|2018|-1.6666666666666683|-1.22|185|
|IBRX|IBRX.O|ImmunityBio|2019|64.75409836065575|-0.43|185|
|IBRX|IBRX.O|ImmunityBio|2020|-37.20930232558139|-0.59|185|
|IBRX|IBRX.O|ImmunityBio|2021|-50.84745762711865|-0.89|185|
|IBRX|IBRX.O|ImmunityBio|2022|-16.853932584269664|-1.04|185|
|IBRX|IBRX.O|ImmunityBio|2023|-10.576923076923064|-1.15|185|
|IBRX|IBRX.O|ImmunityBio|2024|46.086956521739125|-0.62|185|